CNTX

#4405
Context Therapeutics Inc. - Common Stock
0.3 8 USD
-0.10%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.38
0.38
Intervallo Annuale
0.38
3.62
Variazione giornaliera
-9.52%
Variazione Mensile
-36.67%
Variazione di 6 mesi
-82.73%
Variazione Annuale
-55.29%
Chiusura Precedente
0.4 2
Open
0.3 8
Minimo
0.3 8
Massimo
0.3 8
Volume
20
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Context Therapeutics Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Context Therapeutics Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Context Therapeutics Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Context Therapeutics Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Context Therapeutics Inc. current report, Q1 FY2026
8-K

Context Therapeutics Inc. current report, Q4 FY2025

Full document

Business Context and Reporting Period

Company: Context Therapeutics Inc. (CNTX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 17, 2025
Reporting Period: Event date October 17, 2025; Signed October 20, 2025
Business Context: The Company is an emerging growth company listed on The Nasdaq Stock Market. This filing addresses the resolution of a listing compliance issue regarding the Minimum Bid Price Rule.

Key Financial Metrics

This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing focuses exclusively on corporate governance and listing status events.

Material Changes Versus Prior Period

  • Listing Status Change: The Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Rule).
  • Price Performance: The common stock maintained a closing bid price of $1.00 per share or greater for the last 10 consecutive business days leading up to October 17, 2025.
  • Regulatory Timeline:
    • February 27, 2025: Received initial notice of non-compliance.
    • August 28, 2025: Granted an extension until February 23, 2026.
    • October 17, 2025: Received notice that the matter is closed due to regained compliance.

Guidance, Outlook, and Risks

Management Commentary: The filing confirms that Nasdaq considers the compliance matter closed. No forward-looking guidance, financial outlook, or new risk factors were disclosed in this specific report.

Unusual Items: None reported in this filing.

Key Facts for Investor Verification

  • Verify the current trading price of CNTX to ensure it remains above the $1.00 threshold to avoid future non-compliance notices.
  • Confirm the Company's status as an "emerging growth company" and its election regarding extended transition periods for accounting standards.
  • Review prior 8-K filings from February 28, 2025, and September 2, 2025, for full historical context of the delisting risk.
  • Note that this filing contains no financial performance data; investors should refer to the most recent 10-Q or 10-K for financial metrics.

Notizie